Marker Therapeutics, Inc. — Director's Dealing 2015

Nov 13, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TAPIMMUNE INC (TPIV)
CIK: 0001094038
Period of Report: 2011-02-16

Reporting Person: Reddish Mark (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2014-02-26	Common Stock	J	225000	$0.80	Acquired	226667	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2011-02-16	Employee Stock Option (Right to Buy)	$17.00	A	2000	Acquired	2021-02-16	Common Stock (2000)	Direct
2012-04-30	Employee Stock Option (Right to Buy)	$17.00	A	2500	Acquired	2022-04-30	Common Stock (2500)	Direct

Footnotes

F1: Represents common shares issued by the Company in exchange for cancellation of amounts owed to Mr. Reddish of $180,000 in connection with the Company's restructuring in early 2014 in which Series A preferred was issued for the debt and expense reimbursement and subsequently converted into the common stock.

F2: These options were originally issued prior to the Company's most recent February 2014 1 for 100 reverse stock split and amounts reflected are on a post-split basis. The shares have vested.